There is a conversation happening in health and fitness circles right now that deserves a more honest treatment than it's getting. Peptides — short chains of amino acids that act as biological signalling molecules — are everywhere. Your social media feed probably already knows this. BPC-157 for gut healing and tendon repair. TB-500 for injury recovery. KPV for inflammation. GLP-1 agonists like Ozempic reshaping the entire conversation about metabolic health. And somewhere in between, injectable and oral peptide protocols being discussed by biohackers, personal trainers, and functional medicine practitioners alike.
I want to talk about this properly. Not to dismiss it, not to hype it, but to be honest about where the science actually is — and why that distinction matters when we're talking about your health.
What peptides actually are
Before anything else, let's be clear about the biology. Peptides are short chains of amino acids — the same building blocks that make up proteins. Your body produces hundreds of them naturally, using them as signalling molecules that regulate everything from inflammation and tissue repair to gut barrier integrity and immune function. Many pharmaceuticals are peptide-based — insulin is a peptide. GLP-1 agonists like semaglutide are peptide analogues. This isn't fringe science. Peptide biology is mainstream biochemistry.
What's happened in the last five years is that a range of specific peptides — some naturally occurring, some synthetic analogues — have moved from research laboratories and athletic recovery contexts into the wider health and wellness space. The question isn't whether peptides are real or whether they do things. They clearly do. The question is what the evidence actually looks like for the specific peptides being discussed, in humans, at the doses being used.
The evidence picture — honestly
Let me take the three peptides generating the most clinical interest right now.
BPC-157 (Body Protection Compound 157)
A synthetic peptide derived from a protein found in gastric juice. The animal research is genuinely impressive — accelerated wound healing, tendon and ligament repair, gut mucosal healing, neuroprotection, and anti-inflammatory effects across multiple studies. I find the gut healing data particularly interesting given what we know about how many chronic health conditions originate in gut barrier dysfunction. But here is the honest assessment: the human evidence is thin. We have animal studies, case series, anecdotal reports from practitioners, and a growing body of clinical experience among early adopters — but not the randomised controlled trials that would give us confidence to make formal clinical recommendations.
TB-500 (Thymosin Beta-4)
A similar profile — compelling animal data on tissue repair, wound healing, and cardiac protection, with limited human clinical trial data. The injectable form has been used in the athletic and biohacking communities for years. The oral bioavailability question is significant — peptides are typically degraded in the gut, which is precisely why delivery mechanism matters enormously.
KPV
A tripeptide fragment of alpha-melanocyte stimulating hormone with anti-inflammatory and gut-healing properties. The research base is more limited than BPC-157 but the mechanism is well-understood — it activates melanocortin receptors involved in immune regulation and inflammation resolution. Interesting in the context of inflammatory bowel conditions and gut barrier dysfunction.
Ben Greenfield, a well-known US biohacker and author who has collaborated with Paul Chek among others, wrote extensively about injectable BPC-157 protocols years ago and helped bring it into mainstream awareness. That conversation has been happening in practitioner circles for a while. It doesn't make it wrong. It doesn't make it right. It makes it early.
The Quicksilver Scientific question
Quicksilver Scientific is a company I respect. Their liposomal and nanoemulsion delivery technology represents genuine innovation — they've spent years refining the ability to deliver compounds through the gut lining and into systemic circulation in ways that standard oral delivery cannot achieve. Their products are not produced carelessly and their formulation science is legitimate.
So when they invested in bringing liposomal BPC-157 and KPV to market, I paid attention. But I also asked myself an honest question: why would a company of this calibre bring these products to market before stronger human clinical trial data exists?
Their investment is as much in their delivery technology as it is in the specific peptides. It is a calculated bet on a delivery technology platform, not a bet solely on peptide efficacy. That's a meaningful distinction — and it doesn't change the evidence picture.
Their liposomal system solves a real problem — peptide degradation in the gut — and positions them to be the established, quality-controlled option when the human evidence matures. It tells you something about the direction of travel. It doesn't tell you the destination has arrived.
Why established practitioners are using them
I know practitioners I respect who are incorporating BPC-157 and similar peptides into specific clinical protocols. They are not reckless people. They are making informed decisions in consultation with clients who understand they are working with emerging evidence, applying their clinical judgement to the available data, and monitoring outcomes carefully. That is how clinical medicine has always advanced — responsible early adoption by clinicians who understand risk, informed consent, and how to monitor what they're doing.
I am not condemning that approach. I am describing where it sits on the evidence spectrum: this is early adopter territory, not established protocol. There is a difference between "there is no evidence" and "the evidence is preliminary." BPC-157 is not in the first category. It is firmly in the second.
The regulatory reality in the UK
This matters practically. BPC-157, TB-500, and most peptides outside of licensed medicines are in a genuinely murky regulatory position in the UK. They are not licensed medicines. They are not approved food supplements under MHRA definitions. The MHRA has been increasingly active in this space. This has real implications for how these products can be sold, recommended, and used professionally.
I am not going to recommend products to clients that I cannot stand behind from both a clinical and a regulatory perspective. That boundary matters.
My position — and how it shapes what I do
I find peptide biology genuinely fascinating. I follow the research. I watch what respected colleagues are doing with these compounds. I am not dismissing this field — the mechanisms are real, the animal data is compelling, and I expect the human evidence base to grow substantially over the next five to ten years.
Science first. Emotions never. In clinical decisions. The excitement around peptides is real. The social media momentum is real. The biohacker enthusiasm is real. None of that is evidence.
Where I currently sit: I am willing to discuss the emerging evidence with clients who ask. I will not recommend unregulated injectable peptides. For oral liposomal formats from quality-controlled manufacturers, I am watching the evidence and will incorporate them into specific protocols as the clinical data develops and where the risk-benefit calculation is clear. I will not rush that judgement because something is fashionable.
Your health deserves better than clinical decisions driven by what's trending.
What this means for you
If you're curious about peptides — whether that's BPC-157 for gut healing, KPV for inflammation, or GLP-1 mechanisms — the right starting point is always the same one. Understand what is actually driving your symptoms. Test comprehensively. Address the root cause. Targeted, evidence-based intervention outperforms fashionable supplements every time.
The gut healing properties attributed to BPC-157 are interesting. But if you have H. pylori, untreated dysbiosis, low stomach acid, and a compromised gut barrier — the peptide is not your first intervention. The investigation is.
Test, don't guess. That applies to peptides too.
Have your GI-MAP results but no idea what they mean?
The Detective Health GI-MAP Interpretation Guide gives you a personalised interpretation of every marker — plain English, clinical context, and clear next steps. Built on 37 years of functional medicine practice.
Get the GI-MAP Guide — £197 →